252 related articles for article (PubMed ID: 12757626)
1. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.
Chen D; Xia J; Tanaka Y; Chen H; Koido S; Wernet O; Mukherjee P; Gendler SJ; Kufe D; Gong J
Immunology; 2003 Jun; 109(2):300-7. PubMed ID: 12757626
[TBL] [Abstract][Full Text] [Related]
2. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells.
Xia J; Tanaka Y; Koido S; Liu C; Mukherjee P; Gendler SJ; Gong J
J Immunol; 2003 Feb; 170(4):1980-6. PubMed ID: 12574367
[TBL] [Abstract][Full Text] [Related]
3. The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours.
Yang H; Cho NH; Seong SY
Clin Exp Immunol; 2009 Nov; 158(2):174-85. PubMed ID: 19737144
[TBL] [Abstract][Full Text] [Related]
4. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells.
Gong J; Apostolopoulos V; Chen D; Chen H; Koido S; Gendler SJ; McKenzie IF; Kufe D
Immunology; 2000 Nov; 101(3):316-24. PubMed ID: 11106934
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice.
Tanaka Y; Koido S; Chen D; Gendler SJ; Kufe D; Gong J
Clin Immunol; 2001 Nov; 101(2):192-200. PubMed ID: 11683578
[TBL] [Abstract][Full Text] [Related]
6. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
Mukherjee P; Madsen CS; Ginardi AR; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
J Immunother; 2003; 26(1):47-62. PubMed ID: 12514429
[TBL] [Abstract][Full Text] [Related]
7. Recombinant plant-expressed tumour-associated MUC1 peptide is immunogenic and capable of breaking tolerance in MUC1.Tg mice.
Pinkhasov J; Alvarez ML; Rigano MM; Piensook K; Larios D; Pabst M; Grass J; Mukherjee P; Gendler SJ; Walmsley AM; Mason HS
Plant Biotechnol J; 2011 Dec; 9(9):991-1001. PubMed ID: 21740504
[TBL] [Abstract][Full Text] [Related]
8. Expression of B7.1 in a MUC1-expressing mouse mammary epithelial tumour cell line inhibits tumorigenicity but does not induce autoimmunity in MUC1 transgenic mice.
Smith M; Burchell JM; Graham R; Cohen EP; Taylor-Papadimitriou J
Immunology; 1999 Aug; 97(4):648-55. PubMed ID: 10457219
[TBL] [Abstract][Full Text] [Related]
9. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells.
Gong J; Chen D; Kashiwaba M; Li Y; Chen L; Takeuchi H; Qu H; Rowse GJ; Gendler SJ; Kufe D
Proc Natl Acad Sci U S A; 1998 May; 95(11):6279-83. PubMed ID: 9600956
[TBL] [Abstract][Full Text] [Related]
10. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
11. Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines.
Koido S; Enomoto Y; Apostolopoulos V; Gong J
Anticancer Res; 2014 Aug; 34(8):3917-24. PubMed ID: 25075013
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer in mice: effect of murine MUC-1 immunization on tumor incidence in C3H/HeOuj mice.
Xing PX; Poulos G; McKenzie IF
J Immunother; 2001; 24(1):10-8. PubMed ID: 11211144
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of double immunization of mice with mucin 1 and its coding DNA.
Mushenkova N; Moiseeva E; Chaadaeva A; Den Otter W; Svirshchevskaya E
Anticancer Res; 2005; 25(6B):3893-8. PubMed ID: 16309176
[TBL] [Abstract][Full Text] [Related]
14. Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene.
Jaskelioff M; Song W; Xia J; Liu C; Kramer J; Koido S; Gendler SJ; Calderwood SK; Gong J
Oncogene; 2009 Dec; 28(48):4225-36. PubMed ID: 19734944
[TBL] [Abstract][Full Text] [Related]
15. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice.
Koido S; Tanaka Y; Chen D; Kufe D; Gong J
J Immunol; 2002 Mar; 168(5):2111-7. PubMed ID: 11859096
[TBL] [Abstract][Full Text] [Related]
16. Immunisation with 'naïve' syngeneic dendritic cells protects mice from tumour challenge.
Grimshaw MJ; Papazisis K; Picco G; Bohnenkamp H; Noll T; Taylor-Papadimitriou J; Burchell J
Br J Cancer; 2008 Feb; 98(4):784-91. PubMed ID: 18253127
[TBL] [Abstract][Full Text] [Related]
17. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines.
Acres B; Apostolopoulos V; Balloul JM; Wreschner D; Xing PX; Ali-Hadji D; Bizouarne N; Kieny MP; McKenzie IF
Cancer Immunol Immunother; 2000 Jan; 48(10):588-94. PubMed ID: 10630311
[TBL] [Abstract][Full Text] [Related]
18. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
19. Immunization with two recombinant Bacillus Calmette-Guérin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice.
Yuan S; Shi C; Ling R; Wang T; Wang H; Han W
J Cancer Res Clin Oncol; 2010 Sep; 136(9):1359-67. PubMed ID: 20127358
[TBL] [Abstract][Full Text] [Related]
20. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
